<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Mazzaro, Cesare</style></author><author><style face="normal" font="default" size="100%">Zorat, Francesca</style></author><author><style face="normal" font="default" size="100%">Comar, Consuelo</style></author><author><style face="normal" font="default" size="100%">Nascimben, Fabiana</style></author><author><style face="normal" font="default" size="100%">Bianchini, Dario</style></author><author><style face="normal" font="default" size="100%">Baracetti, Stefano</style></author><author><style face="normal" font="default" size="100%">Donada, Carlo</style></author><author><style face="normal" font="default" size="100%">Donadon, Valter</style></author><author><style face="normal" font="default" size="100%">Pozzato, Gabriele</style></author></authors><secondary-authors></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Interferon plus ribavirin in patients with hepatitis C virus positive mixed cryoglobulinemia resistant to interferon.</style></title><secondary-title><style face="normal" font="default" size="100%">The Journal of Rheumatology</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2003</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2003-08-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">1775-1781</style></pages><volume><style face="normal" font="default" size="100%">30</style></volume><issue><style face="normal" font="default" size="100%">8</style></issue><abstract><style  face="normal" font="default" size="100%">OBJECTIVE: Only a small fraction of patients with hepatitis C virus (HCV) positive mixed cryoglobulinemia achieve longterm recovery after interferon (IFN) therapy; we evaluated the effectiveness and safety of combination therapy (interferon plus ribavirin) in nonresponders or those who relapsed after one or more courses of IFN. METHODS: Twenty-seven patients with HCV positive mixed cryoglobulinemia were studied. All were treated with IFN-a2b (3 MU 3 times weekly) for one year, plus daily oral ribavirin 1000 or 1200 mg. RESULTS: Five patients (18.5%) obtained complete recovery from viral infection and from all signs and symptoms of disease. During treatment, most patients (85%) improved clinically. All 5 responders were "relapsers" to the first treatment(s). CONCLUSION: Combination therapy of IFN plus ribavirin could be useful for patients with mixed cryoglobulinemia resistant to IFN as monotherapy.</style></abstract></record></records></xml>